Gilead Sciences, Inc.

1421 articles with Gilead Sciences, Inc.

• Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences

  8/22/2018

  More than 1,200 patients treated to date with momelotinib, including in two Phase 3 trials; ongoing therapy for more than seven years in some patients

• 

  Sierra Oncology Acquires Gilead’s Momelotinib in $198 Million Deal

  8/22/2018

  Vancouver, British Columbia-based Sierra Oncology acquired momelotinib from Gilead Sciences in a deal that could hit $198 million.
• 

  Biotech Movers and Shakers Aug 20

  8/20/2018

  This past week’s roundup of Movers and Shakers in the biotech industry started with a surprise. Gilead Science’s new(ish) chief medical officer was leaving the company six months after taking over the position.
• 

  Taking a Look at Trends in Biotherapeutics

  8/15/2018

  It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs.
• 

  J&J Reports Positive Phase III Data for its Two-Drug HIV Combo

  8/15/2018

  Janssen Pharmaceutical Companies from Johnson & Johnson, confirmed topline data from its Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) trial of its two-drug combination for HIV.
• 

  Gilead CMO Departs, Company Reorganizes Leadership

  8/15/2018

  Foster City, Calif.-based Gilead Sciences reorganized some of its executive leadership team after it was announced that Chief Medical Officer Andrew Cheng is leaving the company to pursue other opportunities.

• Gilead Sciences Announces Executive Promotions

  8/14/2018

  Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company’s medicines and increase focus on reaching patients.

• AHF Files Petition for Review of Gilead AIDS Drug Patent Case with U.S. Supreme Court

  8/13/2018

  In January 2016, AHF filed a federal lawsuit against Gilead Sciences, Inc. and two other defendants alleging drug patent manipulation and anti-trust claims regarding slightly different formulations of tenofovir, a key HIV/AIDS drug found in Gilead’s all-in-one Fixed Dose Combination HIV/AIDS treatments.

• China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection

  8/6/2018

  Genvoya is the First TAF-Based Regimen Approved in China for Adults and Adolescents with HIV

• Louisiana HIV Patients file Federal Personal Injury Cases Against Gilead Over Key HIV Drug

  7/27/2018

  Legal actions filed by two patients with HIV from Louisiana targets Gilead over its promotion of HIV/AIDS medication that causes permanent damage to the kidneys and bones AND over Gilead’s suppression of a safer version of the drug with far less toxicity in order to maximize profits and extend the sales of the initial drug, tenofovir disoproxil fumarate (“TDF”).

• 

  Gilead Boss to Step Down at the End of the Year

  7/26/2018

  Gilead Sciences’ president and chief executive officer, John Milligan, is retiring after 28 years with the company. Gilead is beginning a search for a replacement.

• Gilead Sciences Announces CEO John F. Milligan to Step Down

  7/25/2018

  Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F. Milligan, PhD, will step down as President and Chief Executive Officer.

• Gilead Sciences Announces Third Quarter 2018 Dividend

  7/25/2018

  Gilead Sciences, Inc. announced that the company’s Board of Directors has declared a cash dividend of $0.57 per share of common stock for the third quarter of 2018.

• Gilead Sciences Announces Second Quarter 2018 Financial Results

  7/25/2018

  Product Sales of $5.5 billion

• Gilead Announces New Data on the Impact of Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States

  7/24/2018

  Data Show That States with Highest Use of Truvada for PrEP® Had Significant Declines in New HIV Infections

• 

  GSK Trial Data Shows Strong Support for Two-Drug Regimen Option For Treating HIV Patients

  7/24/2018

  GlaxoSmithKline continues to make headway in the development of two-drug regimens to benefit HIV patients – even those who have high levels of the virus.

• Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors

  7/19/2018

  Kite, a Gilead Company (Nasdaq: GILD), and Gadeta B.V., a privately-held company focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs), have entered into a strategic collaboration to develop novel gamma delta TCR therapies in various cancers.

• 

  Gilead’s Kite and Netherlands’ Gadeta Ink Strategic T-Cell Collaboration

  7/19/2018

  Kite, a Gilead company based in Santa Monica, California, signed an agreement with Utrecht, Netherlands-based Gadeta BV. The companies will work on discovering and developing novel cancer immunotherapies based on gamma-delta T-cell receptors (TCRs).
• 

  Jim Cramer: 3 Biotech Stocks Show Signs They’re Ready to Climb

  7/18/2018

  Despite President Trump circling around semi-regularly to bash the pharmaceutical industry and drug prices, biotech stocks seem to be doing pretty well. The Nasdaq Biotechnology ETF, called the IBB, is up about 17 percent so far this year.

• Gilead Sciences to Release Second Quarter 2018 Financial Results on Wednesday, July 25, 2018

  7/13/2018

  Conference Call and Webcast to Follow